In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Summary

Control group : LAENNEC subcutaneous injection (4 ml)

Experimental group : LAENNEC intravenous injection (10 ml)

Conditions

• Chronic Liver Disease

Interventions

DRUG

LAENNEC (Human Placenta Hydrolysate) IV

Intravenous Injection

DRUG

LAENNEC (Human Placenta Hydrolysate) SC

Subcutaneous Injection

Sponsors & Collaborators

• Green Cross Wellbeing

  lead INDUSTRY

Principal Investigators

• Seung Up Kim, Ph.D. · 50-1, Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea

• Eileen Laurel Yoon, Ph.D. · 222-1, Wangsimni-ro, Seongdong-gu, Seoul, Republic of Korea

• Sang Gyune Kim, Ph.D. · 170, Jomaru-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, Republic of Korea

• Yuri Cho, Ph.D. · 323, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea

• Jung Hwan Yu, Ph.D. · 27, Inhang-ro, Jung-gu, Incheon, Republic of Korea

• Won Sohn, Ph.D. · 29, Saemunan-ro, Jongno-gu, Seoul, Republic of Korea

• Soo Young Park, Ph.D. · 807, Hoguk-ro, Buk-gu, Daegu, Republic of Korea

• Byoung Kuk Jang, Ph.D. · 1035, Dalgubeol-daero, Dalseo-gu, Daegu, Republic of Korea

• Soung Won Jeong, Ph.D. · 59, Daesagwan-ro, Yongsan-gu, Seoul, Republic of Korea

• Young Youn Cho, Ph.D. · 102, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea

• Eun Ju Cho, Ph.D. · 101, Daehak-ro, Jongno-gu, Seoul, Republic of Korea

• Jung Gil Park, Ph.D. · 70, Hyeonchung-ro, Nam-gu, Daegu, Republic of Korea

• Jung Hyun Kwon, Ph.D. · 56, Dongsu-ro, Bupyeong-gu, Incheon, Republic of Korea

• Young Kul Jung, Ph.D. · 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do, Republic of Korea

• Ja Kyung Kim, Ph.D. · 363, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do, Republic of Korea

• Hyun Woong Lee, Ph.D. · 211, Eonju-ro, Gangnam-gu, Seoul, Republic of Korea

• Won Hyeok Choe, Ph.D. · 120-1, Neungdong-ro, Gwangjin-gu, Seoul, Republic of Korea

• Chun Kyon Lee, Ph.D. · 100, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

19 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-07-01

Primary Completion

2026-03-31

Completion

2026-09-30

Countries

• South Korea

Study Locations